It is shown that much advances were made in the treatment of repetitive transcranial magnetic stimulation (rTMS) for neurological and psychiatric diseases in recent years studies. This study aimed to reveal how rTMS exerts it therapeutic effects by regulating competitive endogenous RNAs (ceRNAs) of lncRNA-miRNA-mRNA. The distinction in lncRNA, miRNA and mRNA expression between low-frequency rTMS-treated male SE mice and male SE mice treated with sham rTMS were analyzed by high-throughput sequencing. The Gene Ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were carried out. Gene-Gene Cross Linkage Network was established, and pivotal genes were screened out. qRT-PCR was used to verify gene-gene interactions. In short, there were 1615 lncRNAs, 510 mRNAs and 17 miRNAs differentially expressed between the low-frequency rTMS group and the sham rTMS group. The expression difference of these lncRNAs, mRNAs, and miRNAs by microarray detection were consistent with the resutls by qPCR. GO functional enrichment showed that immune-associated molecular mechanisms and biological processes, GABA-A receptor activity play a role in SE mice treated with low-frequency rTMS. As revealed by KEGG pathway enrichment analysis, differentially expressed genes are correlated to T cell receptor signaling pathway, primary immune deficiency and Th17 cell differentiation signaling pathway. Gene -gene cross linkage network was established on the basis of Pearson's correlation coefficient and miRNA. In conclusion, LF-rTMS alleviates SE through regulating the GABA-A receptor activity transmission, improving immune functions and biological processes, implicating that LF-rTMS may be a viable therapeutic option for epilepsy.